Add some oomph to your portfolio with these ASX growth shares: analysts

If you have room for some new portfolio additions, then it could be worth considering the two ASX growth shares listed below.

Here’s what you need to know about these buy-rated shares:

NextDC Ltd (ASX: NXT)

The first ASX growth share that has been tipped as a buy is data centre operator NextDC.

Goldman Sachs is positive on the company and has just reiterated its buy rating with a $13.60 price target. It believes NextDC is well-placed for strong growth over the next decade.

This morning, the broker commented:

We continue to believe NXT hybrid model puts the company in a strong position to continue gaining share in Enterprise while winning its fair share of hyperscale contracts, supporting a strong earning trajectory over the next decade. This is consistent with its recent bullish AGM commentary expecting to convert its record backlog within the next 6-12 months (i.e. May – Nov 2023). We also expect a detailed update on NXT Asia ambitions in 2023, which although riskier, is well flagged by the company

ResMed Inc. (ASX: RMD)

Another ASX growth share that has just been tipped as a buy is ResMed. It is a medical device company with a focus on sleep treatment solutions.

Morgans is a fan of ResMed and has put an add rating and $37.24 price target on its shares. The broker likes the company due to its strong position in the sleep treatment market and its huge potential in the out of hospital care market.

It commented:

We continue to believe the overall fundamentals remain sound and the company is well positioned, with margin headwinds expected to abate slowly. […] We view RMD as increasingly well positioned as a leading SaaS provider of out of hospital care, with strong underlying sales momentum (+7%) expected to continue, and integration of German-based Medifox Dan (only 6 weeks in 2Q; EPS neutral) offering end-to-end software for nursing and HME customers in Germany.

The post Add some oomph to your portfolio with these ASX growth shares: analysts appeared first on The Motley Fool Australia.

(function() {
function setButtonColorDefaults(param, property, defaultValue) {
if( !param || !param.includes(‘#’)) {
var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
button.style[property] = defaultValue;
}
}

setButtonColorDefaults(“#43B02A”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#43B02A”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
})()

More reading

• 5 things to watch on the ASX 200 on Monday
• $20,000 invested in these ASX shares 10 years ago is worth how much now?
• These ASX 200 tech shares are leading the market today
• ASX 200 healthcare share charges higher as quarterly revenue surges
• 5 things to watch on the ASX 200 on Friday

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Lovisa Holdings Ltd and ResMed Inc. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended ResMed. The Motley Fool Australia has positions in and has recommended ResMed Inc. The Motley Fool Australia has recommended Lovisa Holdings Ltd. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

from The Motley Fool Australia https://ift.tt/0F9UqNh